Biotechnology Industry in India

The biotechnology sector of India is one of the most significant

sectors in enhancing India's global profile as well as contributing to
the growth of the economy.
India is among the top 12 biotech destinations in the world and is
the largest producer of recombinant Hepatitis B vaccine.

Market size

The Indian biotech industry holds about 2 per cent share of the
global biotech industry
With the growth in the customer base and more investments taking
place in the biotech sector, the biotech industry is expected to grow
to around US$ 73.73 billion by the year 2020.
Growing at an average rate of about 20 per cent, India's biotech
industry comprising biopharmaceuticals, bioservices, bioagriculture,
bioindustry and bioinformatics could reach the US$ 7 billion mark by
FY 15.

Investments

Several global companies have aggressively joined hands with Indian
companies

Bristol-Myers Squibb and Syngene International, the contract research
subsidiary of Biocon, have announced a five-year extension of their drug
discovery and development collaboration in India.

The Bhabha Atomic Research Centre (BARC) through its Centre for
Incubation of Technologies (BARCIT) has signed a Memorandum of
Understanding (MoU) with M/s Veena Industries, Nagpur

Cancer Genetics Inc (CGI) has acquired Hyderabad-based genomics
services provider BioServe India for US$ 1.9 million. This will enable CGI
to better position themselves globally in personalised cancer care.

Press Information Bureau (PIB), Media Reports and Press Releases,
Department of Industrial Policy and Promotion (DIPP), Department of
Biotechnology.
Market share of the different biotechnology segments in
India
Global Biotech Industry
Biotech industries globally are soaring high.

Revenue:
Companies in the industry's established biotech centres (the US, Europe,
Canada and Australia) generated revenues of US$98.8b a 10% increase from
2012.

R&D investments:
R&D spending rebounded forcefully, up 14% from the prior year, driven
primarily by a 20% increase in spending in the US.

Net Income:
Net income declined by US$0.8b, driven in part by the US$3.7b increase in
R&D expenditures during the year.

Funding soars:
Biotech companies in North America and Europe raised US$31.6b in 2013,
a sharp increase from the US$28.7b raised in 2012.
Fifty biotechs debuted on the public markets in 2013.

Reference: Beyond borders: unlocking value, EY's 28th annual biotechnology
industry report
SWOT Analysis


Strength
Low price
Debt free and cash rich
Expanding new drug
pipeline
Biocons R&D expertise
Threat
Regulatory risk
Competitive threat
Weakness
Limited Clientele
Narrow Product Range
Opportunities
India has largest
number of diabetics
Expiration of Patents
worldwide